Rishi creates value and reduces risk with its drug development and clinical expertise. Focusing on validated drug targets with associated lead molecules, Rishi in-licenses programs with potential therapeutic promise. Rishi provides scientific management to direct the optimization and drug development process that leads to the submission of an investigational new drug (IND).
Once novel drug candidates have been identified, Rishi supports the early stages of clinical development (Phase I and Phase II) in India, before seeking various commercialization strategies including internally supporting promising programs or joint development agreements. This model utilizes Rishi’s advantages to mitigate early-stage risk while delivering high-value drugs.
